Clinical-MRI correlations in the secondary progressive phase of MS: Lessons from the treatment trials

Journal of the Neurological Sciences

Volumn 206, Issue 2, 2003, Pages 139-144

  Clanet, M ^a   Cassol, E ^a   Manelfe, C ^a   Berry, I ^a,b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU RANGUEIL   (France)

Author keywords

Clinical MRI correlation; Multiple sclerosis; Treatment trials

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL MARKER; GADOLINIUM; INTERFERON BETA SERINE; N ACETYLASPARTIC ACID; PLACEBO;

BRAIN ATROPHY; BRAIN SIZE; CLINICAL FEATURE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DIFFUSION WEIGHTED IMAGING; DISABILITY; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PATIENT MONITORING; PRIORITY JOURNAL; RELAPSE; REMISSION; REVIEW;

EID: 0037441401     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(02)00351-9     Document Type: Article

References (35)

1. Miller D.H., Grossman R.I., Reingold S.C., Mc Farland H.F. The role of MR techniques in understanding and managing MS. Brain. 121:1998;3-24.
2. Trapp B.D., Peterson J., Ransohoff R.M.et al. Axonal transection in the lesions of MS. N. Engl. J. Med. 338:1998;278-285.
3. Kappos L., Polman C., Pozzilli C.et al. Final analysis of the European multicenter trial on IFN beta-1b in SP MS. Neurology. 57:2001;1969-1975.
4. Miller D.H., Molyneux P.D., Barker G.J.et al. Effect of IFN beta-1b on MRI outcomes in SP MS: results of a European multicenter, randomized, double-blind, placebo-controlled trial. Ann. Neurol. 46:1999;850-859.
5. Randomized controlled trial of Interferon-beta-1a in SP MS: clinical results. Neurology. 56:2001;1496-1504.
6. Li D.K.B., Zhao G.J., Paty D.W.et al. Randomized controlled trial of Interferon-beta-1a in SP MS: MRI results. Neurology. 56:2001;1505-1513.
7. Paty D.W., Li D.K.B. Interferon beta-1b is effective in RR MS: 2. MRI analysis of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;662-667.
8. Randomized double-blind placebo-controlled study of interferon beta-1a in RR MS. Lancet. 352:1998;1498-1504.
9. Goodkin D.E. Interferon beta-1b in SP MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology. 54:2000;2352. [Abstract].
10. Stone L.A., Frank J.A., Albert P.S.et al. The effect of interferon beta on BBB disruptions demonstrated by contrast enhanced MRI in RR MS. Ann. Neurol. 37:1995;611-619.
11. van Walderveen M.A., Kamphorst W., Scheltens P.et al. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in MS. Neurology. 50:1998;1282-1288.
12. Barkhof F., van Waesberghe J.H.T., Filippi M.et al. T1 hypointense lesions in SP MS: effect of interferon beta-1b treatment. Brain. 124:2001;1396-1402.
13. Truyen L., van Waesberghe J.H.T., van Walderveen M.A.et al. Accumulation of hypointense lesions (black holes) on T1 spin-echo MRI correlates with disease progression in MS. Neurology. 47:1996;1469-1476.
14. Bitsch A., Kuhlman T., Stadelmann C.et al. A longitudinal MRI study of histopathologically defined hypointense multiple sclerosis lesions. Ann. Neurol. 49:2001;793-796.
15. Brex P.A., Molyneux P.D., Smiddy P.et al. The effect of interferon beta-1b on the evolution of enhancing lesions in SP MS. Neurology. 57:2001;2185-2190.
16. Lossef N.A., Wang L., Lai H.M.et al. Progressive cerebral atrophy in MS: a serial MRI study. Brain. 119:1996;2009-2019.
17. Rudick R.A., Fisher E., Lee J.C.et al. Use of the brain parenchymal fraction to measure whole brain atrophy in RR MS. Neurology. 53:1999;1698-1704.
18. Rudick R.A., Fisher E., Lee J.C.et al. Brain atrophy in relapsing MS: relationship to relapses, EDSS and treatment with interferon beta 1a. Mult. Scler. 6:2000;365-372.
19. Molyneux P.D., Kappos L., Polman C.et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in SP MS. Brain. 123:2000;2256-2263.
20. Kalkers N.F., Bergers E., Castelijns J.A.et al. Optimizing the association between disability and biological markers in MS. Neurology. 57:2001;1253-1258.
21. van Waesberghe J.H., Kamphorst W., De Groot C.J.et al. Axonal loss in MS lesions: MRI insights into substrates of disability. Ann. Neurol. 46:1999;747-754.
22. Bagley L.J., Grossmann R.I., Galetta S.L.et al. Characterisation of white matter lesions in MS and traumatic brain injury as revealed by magnetisation transfer contours plots. AJNR Am. J. Neuroradiol. 20:1999;977-981.
23. Gass A., Barker G.J., Kidd D.et al. Correlation of MTR with clinical disability in MS. Ann. Neurol. 36:1994;62-67.
24. Dehmeshki J., Silver N.C., Leary S.M.et al. Magnetisation transfer ratio histogram analysis of primary progressive and other MS subgroups. J. Neurol. Sci. 185:2001;11-17.
25. Filippi M., Ianucci G., Tortorella C.et al. Comparison of MS clinical phenotypes using conventional and magnetisation transfer MRI. Neurology. 52:1999;588-594.
26. Tortorella C., Viti B., Bozzali M.et al. A magnetisation transfer histogram study of normal appearing brain tissue in MS. Neurology. 54:2000;186-193.
27. Rovaris M., Bozzali M., Santuccio G.et al. In vivo assessment of the brain and cervical cord pathology of patients with primary progressive MS. Brain. 124:2001;2540-2549.
28. Tourbah A., Stievenart J.L., Gout O.et al. Localised proton magnetic resonance spectroscopy in RR versus SP MS. Neurology. 53:1999;1091-1097.
29. Arnold D.L. Magnetic resonance spectroscopy: imaging axonal damage in MS. J. Neuroimmunol. 98:1999;2-6.
30. Rovaris M., Filippi M. The value of new magnetic resonance techniques in MS. Curr. Opin. Neurol. 13:2000;249-254.
31. Horsfield M.A., Lai M., Webb S.L.et al. Apparent diffusion coefficients in benign and SP MS by nuclear MR. Magn. Reson. Med. 36:1996;393-400.
32. Droogan A.G., Clark C.A., Werring D.J.et al. Comparison of MS clinical subgroups using navigated spin-echo diffusion weighted imaging. Magn. Reson. Imag. 17:1999;653-661.
33. Werring D.J., Brassat D., Droogan A.G.et al. The pathogenesis of lesions and NAWM changes in MS: a serial diffusion MRI study. Brain. 123:2000;1667-1676.
34. Nusbaum A.O., Tang C.Y., Wei T.C.et al. Whole-brain diffusion MR histograms differ between MS subtypes. Neurology. 54:2000;1421-1426.
35. Mainero C., De Stefano N., Iannucci G.et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities. Neurology. 56:2001;1331-1334.